1. Inogen, Inc. (INGN) shows promise for growth in the portable oxygen concentrator (POC) space, with a solid first-quarter 2024 performance and a strong product portfolio. Despite stiff competition and forex volatility, the company’s shares have risen 106.4% this year, outperforming the industry and S&P 500.
2. Inogen’s market capitalization stands at $268.7 million, with a projected 56.6% growth for 2024. The P/S ratio of 0.8X makes its valuation attractive compared to the industry. The POC market is expected to reach $3.03 billion by 2030, presenting significant growth opportunities for Inogen.
3. Inogen’s expanding product portfolio includes the FDA-cleared Inogen Rove 4, set to be launched soon with advanced features. The company’s focus on innovation and product development, such as the Inogen Rove 6, positions it well in the market for long-term oxygen therapy solutions.
4. Inogen’s strong second-quarter results, driven by growth in domestic and international sales, highlight its potential for continued success. The company’s strategic focus on hospitals and rental business is expected to drive higher profitability over time, despite facing stiff competition in the LTOT market.
5. While Inogen faces challenges like intense competition in the LTOT market and forex volatility impacting overseas revenues, the company’s improving estimate revision trend for 2024 is a positive sign. With a Zacks Consensus Estimate for revenues at $327 million, Inogen remains a key player to watch in the medical instruments industry.

Read more at Nasdaq: Here’s Why You Should Add Inogen Stock to Your Portfolio Now